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Summary
BACKGROUND: In Switzerland, the first course of intra-
venous steroids for treatment of episodes of demyelinating
CNS disease is usually administered in an inpatient setting.
We prospectively evaluated short term tolerance of treat-
ment with special emphasis on sleep quality.
METHODS: Patients with a first event of presumed demy-
elinating disease (CIS), multiple sclerosis relapses (MS) or
sub-acute disease progression were treated with a 5-day re-
gimen of intravenous methylprednisolone (IVMP) in our
inpatient clinic. Patients’ experience was documented by
self-report questionnaires including a standardised depres-
sion scale (ADSL). Laboratory tests were performed on
a routine basis. Fasting glucose, blood pressure and pulse
were measured before every infusion. Activity and sleep
patterns were analysed by wrist actigraphs during the 5 day
infusion period and at follow-up after 1–2 months.
RESULTS: A total of 66 patients participated in the study.
Of these, 55 were steroid treatment naïve, and 11 patients,
who had received intravenous steroid relapse treatment be-
fore, were admitted because of disabling symptoms. Mood
disturbances were reported before steroid treatment,
however significantly less often at the end of the steroid
pulse and during follow-up. Sleep efficiency as measured
by wrist actimetry was high before, during and after steroid
treatment.
CONCLUSION: Therapy was well tolerated without
severe side effects in CIS and MS patients. Sleep efficiency
was not disturbed. In conclusion there are no obstacles
to change from an inpatient to an outpatient setting for
the steroid treatment of relapses in MS and CIS, but rare
psychotic reactions to steroid treatment are not predictable.
Key words: multiple sclerosis; intravenous steroid
treatment; sleep / activity pattern
Introduction
Intravenous corticosteroids are the mainstay for treatment
of relapses of demyelinating CNS diseases [1–6]. It hastens
recovery and seems to prevent relapse progression [7]. To
date, there is no sufficient evidence for long term prevent-
ive strategies with corticosteroids [8–11]. A recent trial of
monthly pulses of methylprednisolone in combination with
interferon beta-1a revealed no effect on disability progres-
sion [12]. In another recent trial, oral methylprednisolone
given in pulses every 4 weeks as an add-on therapy to
subcutaneous interferon beta-1a in patients with relapsing-
remitting multiple sclerosis (RR-MS) led to a reduction
in relapse rate [13]. However, the study involved a small
number of patients, had a high dropout rate, and sleep dis-
turbance and neurological and psychiatric symptoms were
frequently recorded as adverse events in the methylpred-
nisolone group. Bone mineral density had not changed after
96 weeks. Another study showed slowing of progression of
atrophy as seen with MRI in RR-MS patients by monthly
steroid-therapy [14].
Oral application of high dose prednisone seems to be
equally effective, but involves a higher risk of side effects
[3, 5, 15].
The first cycle of high dose intravenous pulse therapy is
usually administered in hospital for safety reasons. Poten-
tially severe side effects include epileptic seizures,
psychotic reactions, cognitive decline, venous thrombosis,
anaphylactic reactions and cardiac arrhythmias [2, 4, 5,
16–21]. If the first therapy cycle is well tolerated, subse-
quent cycles are usually applied with intravenous methyl-
prednisolone (IVMP) in an outpatient setting unless pa-
tients require hospitalisation for disabling relapse symp-
toms. A British trial evaluated home application of IVMP
by specialised nurses to be superior as compared to out-
patient administration in terms of patient satisfaction [22].
Therapy was generally well tolerated in this trial of patients
with definite multiple sclerosis (MS).
Patients with first episodes of demyelinating disease were
usually referred to our in-patient clinic for diagnostic work-
up and had not been treated with intravenous steroids be-
fore. Our aim was to evaluate the safety of steroid therapy
with regard to potential application in a day care unit.
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 1 of 6
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
15
95
1 
| 
do
wn
lo
ad
ed
: 
8.
5.
20
16
Methods
Patients
Patients were recruited after emergency or elective admis-
sion to the neurological in-patient clinic of the University
Hospital in Berne from October 2004 to February 2006. Pa-
tients with clinically isolated syndrome (CIS), RR-MS, and
secondary (SP) or primary progressive (PP) MS were eli-
gible for this study, if IVMP therapy was planned for treat-
ment of acute exacerbation (CIS and RR-MS) or accentu-
ated progression of symptoms (SP and PP-MS). The local
ethics committee approved the study and all patients gave
written informed consent for study participation. All pa-
tients were treated in an in-patient setting. Follow-up eval-
uation after 4 to 8 weeks was obtained from 48 patients.
Clinical follow-up data were collected from 12 patients in
remission up to 3 months. Follow-up data could not be ob-
tained in 6 patients.
Procedures
Patients received IVMP 500 mg per day for five days. Infu-
sions were administered over one hour during the daytime,
preferably in the hours before noon. The IVMP course was
followed by oral tapering of prednisone as follows: pred-
nisone 100 mg for 3 days with a reduction to 50 mg, 25 mg
and 12.5 mg for 3 days each. Proton pump inhibitors to pre-
vent gastric side effects and calcium tablets to prevent osteo-
porosis were routinely administered during IVMP treatment.
We created a questionnaire for patients’ self-evaluation re-
garding the impact of the relapse, sleep disturbance, use of
sleeping pills and day time fatigue before, during and after
treatment. Fatigue included both physical and mental fa-
tigue, which specifically meant fatigue perceived as muscle
weakness and fatigue perceived as loss of attention or
sleepiness. Furthermore systemic adverse effects were
evaluated. In addition, we evaluated for depressive decline
with the ADS-L questionnaire, the German version of the
CES (Centre of epidemiological studies Depression scale)
at baseline, after the IVMP therapy and at the follow-
up visit. Sleep-wake patterns were analysed by wrist acti-
graphs during the infusion period (n = 31) and at follow-up
(n = 17). An actigraph is an acceleration-sensitive, watch-
like device that is typically carried on the non-dominant
arm and generates a voltage each time the wrist with the
actigraph is moved. By using an actigraph, motor activity
can be monitored continuously over a prolonged period
during wakefulness and sleep.
Laboratory tests were performed on a routine basis. Fasting
glucose, blood pressure and pulse were measured before
every infusion.
Upper extremity function was measured before treatment,
at day five and at day 30 by a brief, standardised, quantitat-
ive test called the Nine-hole peg test [23].
Statistical analysis
Longitudinal analysis of ordinal and metric data was per-
formed using the Wilcoxon-Signed-Rank-Test (p-value,
median differences with 95% Confidence Interval (CI)).
Statistical analysis of longitudinal categorical data was per-
formed using the McNemar-Test (p-value)
Results
A total of 66 patients were included in the study. Table 1
shows the patient characteristics. The majority were CIS
and RR-MS patients. Concomitant disease and vascular
Table 1: Baseline characteristics.
CIS (n = 36) MS (n = 30) Total (n = 66)
Women 28 (77%) 20 (66%) 48 (73%)
Age in years (median and range) 33 (16.–53.) 41 (26–74) 36 (16.–74)
Disease course
Relapsing-remitting
Secondary progressive
Primary progressive
–
–
–
20 (66%)
5 (16%)
5 (16%)
–
–
–
First steroid course
Previous steroid courses
36
–
19 (63%)
11 (37%)
55 (83%)
–
Delay between first relapse symptoms and steroid
infusion, days median (min;max) 7.0 (1; 40) 12.4 (3; 28) 7.5 (1; 40)
EDSS
median (min; max) 2.5 (1; 6.5) 3.8 (1.5; 7) 3 (1; 7)
ADS-L
median (min; max) 11 (3; 37) 12 (5; 41) 12 (3; 41)
Table 2: Adverse effects indicated by the patients during steroid infusion days 1–5.
CIS MS Total
Taste alteration 24/34 (71%) 14/29 (48%) 38/63 (60%)
Dizziness 10/35 (29%) 9/29 (31%) 19/64 (30%)
Facial flush 16/35 (46%) 16/29 (55%) 32/64 (50%)
Sweating 11/35 (31%) 7/29 (24%) 18/64 (28%)
Palpitations 8/35 (23%) 2/29 (7%) 10/64 (16%)
Dry mouth 15/35 (43%) 12/29 (41%) 27/64 (42%)
Tremor 3/35 (9%) 4/29 (14%) 7/64 (11%)
Hearing problems 4/35 (11%) 2/29 (7%) 6/64 (9%)
Visual disturbance 4/35 (11%) 1/29 (3%) 5/64 (8%)
Hallucinations 0/35 0/29 0/64
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risk factors were present as follows: Hypertension (11 pa-
tients), diabetes (2 patients), hypercholesterolemia (2), his-
tory of hepatitis (2), migraine (1), factor V Leiden mutation
(1), hypothyroidism (1), and folic acid deficiency (1). The
majority of patients (83%) received their first steroid treat-
ment, 36 patients with CIS and 19 patients with RR-MS.
Median EDSS (Expanded disability status scale; a method
of quantifying disability in MS) was lower in CIS (2.5)
compared to RR-MS patients (4.0) as expected. At
baseline, five patients (2 CIS, 2 RR-MS, 1 PP-MS) scored
higher than 23 on the ADS-L questionnaire, indicating de-
pression. On day 5, three patients scored higher than 23;
two (one CIS, PP-MS) better and one (CIS) worse, than at
baseline. ADS-L scores at follow-up visits did not indicate
depression in all patients.
Systemic adverse effects based on self-reporting during in-
fusions are depicted in table 2. Mood disturbances were
mentioned by 56% of all patients at baseline, but during the
five-day infusion period and at the follow-up visit depress-
ive complaints were significantly less frequent compared
to the pre-treatment situation (table 3b). Analysis of CIS
and MS patients separately revealed a significant improve-
ment of depressive symptoms only for MS patients from
baseline to the infusion period. Analysis of ADS-L z-scores
revealed significant improvement for MS patients during
the infusion therapy. Significant improvement of ADS-L z-
score at follow-up was shown for the entire group.
Fatigue, sleep quality and use of sleeping pills were also
analysed separately for CIS and MS patients.
Fatigue was present in almost 78% of CIS patients before
steroid therapy and was reported by all patients during the
infusion period. Fatigue was significantly less frequent in
CIS patients at the follow-up visit as compared to the 5 day
infusion period.
Poor sleep quality was mentioned in 59% of CIS patients
at baseline, and 26% used sleeping pills before and during
IVMP therapy. Sleep quality had significantly improved at
the follow-up evaluation as compared to the infusion peri-
od. At follow-up, 50% of the CIS patients mentioned fa-
tigue and 13% still reported sleep problems, but none were
taking sleeping pills.
For MS patients data concerning fatigue showed no signi-
ficant change before and during steroid therapy. At follow
up, MS patients reported fatigue more often than CIS pa-
tients (87% vs. 50%). At the follow-up visit, sleep quality
had significantly improved in MS patients. The measure-
ment of nocturnal inactivity by wrist actigraphy demon-
strated a significantly reduced time spent in bed during the
follow-up period at home as compared to the in-hospital in-
fusion period in CIS patients. Presumed sleep efficacy as
measured by % inactivity during bedtime did not show a
significant difference between the infusion period and the
follow-up days. More details are given in tables 4 and 5
Clinical outcome measures improved after steroid therapy.
For CIS patients the mean EDSS at baseline was 2.8 and
1.86 at follow up.
The mean EDSS at baseline for MS patients was 3.93 and
3.46 at follow-up.
Mean baseline values of the Nine Hole Peg Test (NHPT),
a brief quantitative test of hand dexterity, were as follows:
CIS patients, right hand: day 1: 28s, day 5: 24s, follow-up:
17s; left hand: day 1: 23s, day 5: 26s, at follow-up 17s.
For MS patients the mean values of the NHPT for the right
hand at baseline were: day one: 28s, day 5: 27 s, follow-up:
21 s; for the left hand: day one: 24 s, day 5: 23 s, at follow
up: 21s.
Discussion
This study was undertaken to investigate the tolerance and
adverse effects of IVMP treatment in patients with clinical
isolated syndrome or relapses in multiple sclerosis. To date
there is no evidence that IVMP is more effective than oral
administration [3]. However, given the small number of
patients studied and methodological problems the equival-
ence is still questionable. Most departments including our
department continue to use the conventional intravenous
(i.v.) route. There are mainly two reasons that we have not
Table 3a: Mood disturbance, ADS-L scores before, during and after steroid therapy.
CIS MS Total
Before steroid therapy
Mood disturbance
ADS-L (z-score, median, n)
15/30 (50%)
–0.22 (31)
16/25 (64%)
0.600 (24)
31/55 (56%)
0.02 (55)
During i.v. steroid therapy
Mood disturbance
ADS-L (z-score, median, n)
10/32 (31%)
–0.0200 (23)
11/26 (42%)
0.200 (22)
21/58 (36%)
0.02 (45)
After steroid therapy
Mood disturbance
ADS-L (z-score, median, n)
2/14 (14%)
–0.625 (12)
3/12 (25%)
0.5800 (13)
5/26 (19%)
0.58 (25)
Table 3b: Longitudinal analysis of mood disturbance (p value).
Steroid Therapy CIS MS Total
Before – During 0.343 0.041 0.024
Before – Follow-up 0.248 0.131 0.027
During – Follow-up 1.000 0.221 0.131
Table 3c Longitudinal analysis ADS L-z-score (p value/median difference/ 95%CI).
Steroid Therapy CIS MS Total
Before-During 0.628 (–0.1; –0.575, 0.340) 0.020 (0.29; 0.060, 0.495) 0.340 (0.1075; -0.140, 0.335)
Before-Follow-up 0.375 (0.3; –0.43, 0.83) 0.148(0.71; –0.165, 1.085) 0.072 (0.5125; -0.045, 0.830)
During-Follow-up 0.067 (0.6375; –0.08, 1.20) 0.289(0.23; –0.56, 1.25) 0.029 (0.51; 0.020, 0.935)
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yet categorically changed our inpatient regimen to an out-
patient setting with i.v. or oral medication: 1. Too many
patients complain of sleep disturbance and mood disorder
and, 2. a small number of patients become psychotic while
receiving steroids. In this study steroid therapy was well
tolerated. About half of the symptoms which patients com-
plained about were well known side effects.
Table 4a: Fatigue, poor sleep quality, sleeping pills: CIS patients.
CIS Fatigue Poor sleep quality Use of sleeping pills
Before steroid therapy 25/32 (78%) 20/34 (59%) 9/35 (26%)
Steroid therapy day 1 33/33 (100%) 20/34 (59%) 11/35 (31%)
Day 2 33/33 (100%) 20/34 (59%) 10/35 (29%)
Day 3 33/33 (100%) 20/34 (59%) 12/35 (34%)
Day 4 33/33 (100%) 21/35 (60%) 7/35 (20%)
Day 5
After steroid therapy
33/33 (100%)
9/17(50%)
Not assessed
2/15(13%)
Not assessed
0/18(0%)
Table 4b: Fatigue, poor sleep quality, sleeping pills: MS patients.
MS Fatigue Poor sleep quality Use of sleeping pills
Before steroid therapy 23/27 (85%) 19/29 (66%) 6/29 (21%)
Steroid therapy day 1 26/28 (93%) 15/29 (52%) 11/29 (38%)
Day 2 26/28 (93%) 13/29 (45%) 11/29 (38%)
Day 3 26/28 (93%) 20/34 (59%) 12/29 (41%)
Day 4 26/28 (93%) 17/28 (61%) 10/29 (34%)
Day 5 26/28 (93%) Not assessed Not assessed
After steroid therapy 13/15 (87%) 4/14 (29%) 2/13 (15%)
Table 4c: Longitudinal analysis: Fatigue, poor sleep quality, sleeping pills . Before/During Steroid Therapy at follow-up.
p value Median differences 95% CI median differences
Fatigue
CIS Before- during 0.495 –0.25 [–1.5 , 0.5]
CIS Before-Follow-up 0.208 0.75 [–1 , 2]
CIS During-follow-up 0.011 0.75 [0 ,2]
MS Before-During 0.607 –0.5 [–1 , 1]
MS Before-Follow-up 0.965 –0.25 [–1.5 , 1.0]
MS During -Follow-up 1.000 0.25 [–1.5 , 1.0]
Impaired Sleep quality
CIS Before-During 0.920 0.125 [–0.5 , 0.5]
CIS Before-Follow-up 0.055 0.75 [–1, 2]
CIS During-Follow-up 0.020 0.875 [0.0, 1.5]
MS Before-During 0.761 0.125 –0.5 1.0
MS Before-Follow-up 0.031 0.75 0 2
MS During-Follow-up 0.027 1.125 0 2
Sleeping pills
CIS Before-During 0.134
CIS Before-Follow-up 1.000
CIS During-Follow-up 0.134
MS Before-During 0.016
MS Before-Follow-up 1.000
MS During-Follow-up 0.041
Table 5a: Nocturnal inactivity periods (% inactivity) and time in bed measured by actimetry during (day 1–5) and after (day 31–35) steroid therapy.
Day 1 2 3 4 5 31 32 33 34 35
Hours in bed
median
(min; max)
8.3
(4.9; 10.4)
n = 31
8.5
(6.4; 15.4)
n = 31
8.5
(5.9; 13.9)
n = 30
8.9
(6.1; 11.7)
n = 25
8.5
(5.6; 10.3)
n = 11
8.0
(4.4; 10.7)
n = 17
7.5
(5.7; 10.6)
n = 16
7.1
(5.3; 13.3)
n = 16
7.8
(4.3; 12.6)
n = 15
7.9
(6.1; 10.7)
n = 13
CIS
patients
% inactivity
median
(min; max)
93.8
(64; 98)
93.4
(79; 99.8)
93.5
(65.6; 100)
93.1
(50.4; 99.8)
97.4
(90.7; 100)
94.7
(49.6; 98.9)
93.3
(85.1; 98.6)
96.3
(70.9; 98.3)
96.1
(90.2; 98.5)
94.9
(78.9; 97)
Hours in bed
median
(min; max)
7.9
(5.1; 11.4)
n = 29
8.4
(4.9; 18)
n = 28
8.5
(5.8; 12)
n = 28
8.9
(4.6; 16)
n = 23
8.9
(7.7; 10.8)
n = 4
8.2
(5.5; 10.5)
n = 16
8.3
(5.5; 9.9)
n = 16
7.3
(6.3; 12.6)
n = 16
8.4
(5.4; 10.3)
n = 14
7.8
(6.3; 9.4)
n = 10
MS
patients
% inactivity
median
(min; max)
93.1
(64.7; 98.7)
93.2
(53.4; 99.8)
93.7
(80.8; 97.9)
95.1
(86.9; 99.7)
93.1
(65.7; 98.1)
94.5
(79.3; 98.2)
92.1
(45.1; 98.2)
95.3
(68.5; 99.1)
90.9
(73.4; 98.6)
96.3
(90.5; 96.9)
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None of the patients had psychotic side effects. About half
of the patients reported mood disturbance before steroids
were started. Only five patients exceeded the cut-off score
on the ADS-L for mood disturbance indicating depression
before steroids, and four of them improved during ther-
apy. During therapy and in the remission period mood dis-
turbances were significantly less frequent than at baseline.
This is also reflected by the improvement of the ADS-L
Depression score. Disease inherent mood alteration during
relapse activity and reactive mood disorders are possible
explanations for this evolution. However, during the remis-
sion period mood disturbances were still reported by about
19% of patients. All patients reported fatigue before and
during therapy. Sleep quality and fatigue had significantly
improved at the follow-up visit in CIS patients as com-
pared to the infusion period. Challenges of dealing with the
new situation and diagnosis of “CIS” could be the reas-
on for this observation. At follow up visits MS patients re-
ported fatigue more often (87%) than CIS patients (50%),
possibly reflecting disease inherent fatigue. A remarkable
proportion of patients missed the follow up visit, there-
fore a selection bias may account for this observation. Un-
like the complaints of sleep disturbances, wrist actigraphy
demonstrated high sleep efficiency which is discrepant to
the complaints of the patients. However, this could be ex-
plained by times when patients lie awake quietly. With the
actigraphy we detect inactivity but not insomnia, and this
could potentially explain the discrepancy of actigraphy and
the subjective feeling of insomnia by many patients. When
the patient lies awake quietly he is inactive and sleepless,
but actigraphy would indicate sleep.
To summarise, no severe adverse effects were noted in CIS
and MS patients during IVMP treatment. From this point
of view there is no reason not to change from an inpatient
management of IVMP to an outpatient management when
patients receive IVMP for the first time. With the small
sample analysed rare adverse effects such as psychosis are
not likely to be detected. Therefore clinical vigilance is of
crucial importance when IVMP is administered in an out-
patient setting. Patients with known depression or psychos-
is should still be admitted to hospital if steroid treatment is
required, and should be treated only under special precau-
tions and adoption of psychiatric medication and sedatives.
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